Drug intelligence / Profile preview

allergen extract from phleum pratense pollen, glutaraldehyde-modified

Development stage
Phase 3
Lead developer
Roxall Medizin
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

This drug is a glutaraldehyde-modified allergen extract, known as an allergoid, derived from the pollen of *Phleum pratense* (Timothy grass). Developed by ROXALL Medizin GmbH, it is used in allergen immunotherapy (AIT) for patients with allergic rhinitis, allergic rhinoconjunctivitis, and well-controlled grass pollen-induced asthma. The glutaraldehyde modification process cross-links the allergen proteins, which significantly reduces their IgE-binding capacity (allergenicity) while preserving their ability to stimulate T-cells (immunogenicity). This allows for the administration of higher allergen doses with a reduced risk of systemic allergic reactions. The therapy works by inducing immunological tolerance, shifting the immune response from a Th2-dominated allergic profile toward a Th1/Treg-mediated response and stimulating the production of allergen-specific IgG4 blocking antibodies.

Brand names
CLUSTOIDCLUSTO-GRAS
Other names
Timothy grass pollen allergoidPhleum pratense pollen allergoidModified allergen extract Phleum pratense
02

Targets

BCR (Immunoglobulin G B Cell Receptor)γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on allergen extract from phleum pratense pollen, glutaraldehyde-modified.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on allergen extract from phleum pratense pollen, glutaraldehyde-modified.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call